1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

EGFR

EGFR (epidermal growth factor receptor; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factorfamily (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR exists on the cell surface and is activated by binding of its specificligands, including epidermal growth factor and transforming growth factor α (TGFα). EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of several tyrosine (Y) residues in the C-terminal domain of EGFR occurs.

EGFR Related Products (84):

Cat. No. Product Name Effect Purity
  • HY-15772
    AZD-9291 Inhibitor 99.95%
    AZD-9291 is a third generation irreversible EGFR tyrosine kinase inhibitor with selectivity against mutant versus wild-type forms of EGFR, shows an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M in EGFR recombinant enzyme assay.
  • HY-50895
    Gefitinib Inhibitor 99.95%
    Gefitinib is an inhibitor that specifically binds and inhibits the EGFR tyrosine kinase, with the IC50 value of 2-37 nM in NR6wtEGFR cells.
  • HY-50898
    Lapatinib Inhibitor 99.90%
    Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.2 and 9.8 nM, respectively.
  • HY-10261
    Afatinib Inhibitor 99.58%
    Afatinib is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-50896
    Erlotinib Inhibitor 99.82%
    Erlotinib inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-104065
    Pyrotinib Inhibitor 98.40%
    Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.
  • HY-19816A
    Avitinib maleate Inhibitor >98.0%
    Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68 nM.
  • HY-101095
    NT-113 Inhibitor
    NT-113 is an irreversible pan-ERBB inhibitor, with IC50 of 0.4, 4.35, 4.18 and 2.08 nM for EGFR, EGFR (T790M), ERBB2/HER2 and ERBB4/HER4, respectively, exhibiting anti-glioma activities.
  • HY-12000
    AG-490 Inhibitor 98.86%
    AG-490 is an tyrosine kinase inhibitor, inhibits EGFR and Stat-3.
  • HY-12008
    Erlotinib Hydrochloride Inhibitor 99.91%
    Erlotinib hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-14596
    Genistein Inhibitor 99.64%
    Genistein is a potent inhibitor of the protein tyrosine kinase (PTK) activity of the EGFR in vitro with an IC50 of 0.7 μg/mL (0.6 μM).
  • HY-32721
    Neratinib Inhibitor 99.54%
    Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.
  • HY-15772A
    AZD-9291 mesylate Inhibitor 99.95%
    AZD-9291 mesylate is a third generation irreversible EGFR tyrosine kinase inhibitor with selectivity against mutant versus wild-type forms of EGFR, shows an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M in EGFR recombinant enzyme assay.
  • HY-13524
    AG-1478 Inhibitor 99.83%
    AG-1478 is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM.
  • HY-19730
    Olmutinib Inhibitor 99.95%
    Olmutinib (HM61713; BI-1482694) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with IC50 values of 9.2 nM and 10 nM in HCC827 and H1975 cell, respectively.
  • HY-10261A
    Afatinib dimaleate Inhibitor 99.81%
    Afatinib dimaleate is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-12872
    EGF816 Inhibitor 99.85%
    EGF816 is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min−1 on EGFR(L858R/790M) mutant, respectively.
  • HY-13272
    Dacomitinib Inhibitor 99.91%
    Dacomitinib is a specific and irreversible inhibitor of the ERBB family of kinases with IC50 of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
  • HY-16069
    Irbinitinib Inhibitor 99.57%
    Irbinitinib (ARRY-380; ONT-380) is a potent and selective HER2 inhibitor with an IC50 of 8 nM.
  • HY-18750
    AZD3759 Inhibitor 99.61%
    AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor.